Eli Lilly Nears Billion-Dollar Acquisition of Kelonia - WSJ
U.S. pharmaceutical company Eli Lilly is in advanced talks to buy biotechnology company Kelonia Therapeutics for more than $2 billion, the Wall Street Journal reports.
ANNONS
Kelonia is developing a next-generation CAR-T treatment for multiple myeloma, a type of blood cancer, that could simplify today’s therapies by avoiding both chemotherapy and individual cell manufacturing. The company’s candidate is in an early clinical stage. An acquisition would strengthen Eli Lilly’s position in blood cancer and broaden its portfolio.
The deal is part of Lilly’s increased acquisition activity, financed by strong sales of weight-loss drugs. Recently, the company has also bought Centessa Pharmaceuticals for about $6.3 billion and agreed to acquire Orna Therapeutics for up to $2.4 billion and Ventyx Biosciences for around $1.2 billion.
